Broadcom's custom AI chips and strong network infrastructure have high demand for high standards.
Despite the increased trade war issues, Shopify's diversified and resilient business model makes it attractive.
Vertex Pharmaceuticals and Intuitive Surgical are both tracks in the medical field.
In 2025, Wall Street is growing concerns about the U.S.-China trade war, escalating geopolitical pressures, escalating economic uncertainty and growing fears of recession. Benchmark S&P 500 In 2025, the index fell by nearly 4.7%.
However, this market volatility and sell-off provides retail investors with attractive entry opportunities. Such as Broadcom (NASDAQ: AVGO),,,,, Shopping (Nasdaq: Shop),,,,, Pinpoint Drugs (NASDAQ: VRTX)and Intuitive surgery (NASDAQ: ISRG) Now it can be a wise choice. This is why.
Where to invest $1,000 now? Our team of analysts just revealed what they think is 10 Best Stocks Buy it now. continue"
Broadcom's stock is nearly 22% compared to its recent surge in December 2024 due to the escalation of the trade war between the United States and China. However, the stock remains an attractive buy due to its powerful artificial intelligence (AI) strategy and strong financial situation.
Unlike many other CHIP players, these chip players focus on developing universal accelerators that can cater to multiple applications, while Broadcom focuses on custom XPUs tailored to the specific needs of its super-rated customers. This customization makes the chip suitable for specific workloads, providing super-rating customers with higher performance and energy efficiency.
The strategy appears to pay off, as management estimates that the addressable market for the three existing super-rating customers will be $60 billion to $90 billion by 2027. This prediction does not include the other four super rating customers who have designed custom XPUs. In addition, Broadcom's networking solutions are also in high demand, as they are a key component of large AI clusters.
Broadcom also has a strong financial position, which proves that year-on-year revenue has increased by 25% in the most recent quarter and 44% year-on-year operating revenue growth for the first quarter ended February 20025.
Broadcom trades at 29.4 times forward earnings, well below its five-year average of 70.5. Therefore, given its upward potential and reasonable valuation, this may be the time to pick a small number of shares of the stock.
E-commerce giant Shopify is currently down nearly 25% from its near high in February 2025. Nevertheless, the company released a steady 31% year-on-year growth in the most recent quarter, with an operating margin of 17%, and an annual total commodity value (GMV) of $300 billion in annual stock prices, which seems to be a share of the price sale of their stock investors, which is the share of retail investors.
While Shopify doesn't sell anything online, it offers a complete technology-driven omnichannel setup so that merchants can connect with customers digitally. Once known for focusing on SMEs, the company now caters to several larger global brands.
Shopify also believes that there is great potential for growth in the international market and has made strategic investments in localization, compliance improvements and local payment methods. Offline trade and B2B trade have also become strong growth opportunities. Shopify is also committed to using advanced AI technologies to help new businessmen launch and scale at higher productivity on its platform.
The stock trades at a forward price-to-earnings ratio of 66.2, which is greater than its five-year average of 39. However, considering its diversified business model, multiple growth drivers and resilience, a wealthy valuation seems reasonable. Analysts also expect revenue to rise 25.3% year-on-year to $2.33 billion. This is a healthy growth forecast, even if the increased tariff war could affect it indirectly through its merchant customers. So, stocks now seem to be an attractive option.
Vertex Pharmaceuticals shares grew nearly 23.9% in 2025. However, the healthcare giant still has huge growth potential.
The vertex continues to dominate the cystic fibrosis (CF) market with Trikafta/kaftrio and more effective, more convenient next-generation Alyftrek. In 2024, Trikafta/kaftrio accounted for US$10.2 billion of the company's net product revenue. As Trikafta's patent protection extends into 2037, the company has strong revenue visibility.
The apex also makes it feel in blood diseases, pain management, diabetes and kidney disease. Journavx is the first new non-opioid painkiller approved by the U.S. Food and Drug Administration (FDA) in more than 20 years, with a potential market of 80 million patients suffering from various types of moderate to severe acute pain. The recently launched Casgevy has also proven to be a transformative one-time treatment for patients with certain blood diseases.
The company showed strong financial strength, with $11.2 billion in cash and almost no debt. Given the company's many strong headwinds and solid finances, the forward value of 24.2 doesn't seem expensive, making the stock worth buying now.
Leading surgical robotics players’ intuitive surgery stocks are mostly flat in 2025. However, as its global DA VINCI installs more than 10,000 systems worldwide in 70 countries, the company's stock faces a rapidly growing stock in the coming years, despite the challenges posed by import and export trade institutions, due to the ongoing trade war.
Intuitive surgery showed strong operational and financial performance, with a year-on-year increase of 18.5% on a daily adjustment basis and a 19% increase in revenue in the first quarter of 2025. The company's latest DA Vinci 5 System is gaining strong momentum and achieved nearly 147 systems in the first quarter and nearly 147 systems in the first quarter.
Intuitive surgery also hopes to provide additional features for its DA Vinci system, such as real-time surgical video review, mandatory feedback technology and real-time 3D model reviews.
The company also continues to develop its case insight computing technology, which has provided data sets such as video, kinematic energy, and forced data for more than 22,000 programs executed by the DA Vinci system. This helps surgeons effectively review program videos to identify operational and clinical insights. Intuitively, these computing tools will be the main differentiator in the long run.
In this context, while forward value at 56 times seems expensive, wealthy valuations reflect the company's market advantages and significant growth prospects - so wise even at higher levels.
Before you buy stocks on Broadcom, consider the following:
this Motley Fool Stock Advisor The analyst team just confirmed what they think is 10 Best Stocks Investors buy now…and Broadcom is not one of them. Ten stocks with layoffs could generate monster returns in the coming years.
When to consider Netflix On this list on December 17, 2004...If you invested $1,000 when you suggested, You will have $623,685! * Or when Nvidia This list was listed on April 15, 2005...If you invested $1,000 when you suggested, You will have $701,781! *
Now, it's worth noting Stock ConsultantThe overall average return is 906% - Compared to market sprints 164% For the S&P 500 index. Don't miss the latest top ten list, available when you join Stock Consultant.
View 10 stocks »
*Stock consultant returns as of April 28, 2025
Manali Pradhan has no position in any of the stocks mentioned. Motley fool has a place and recommends intuitive surgery, Shopify and Vertex Pharmaceuticals. Motley Fool recommends Broadcom. Motley Fool has a disclosure policy.
Stock Market Sell: There are 4 Unwise Stocks, Originally published by Motley Fool